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Background: Acylglycerol kinase (AGK) is reported to be overexpressed in multiple cancers. The clinical significance
and biological role of AGK in breast cancer, however, remain to be established.
Methods: AGK expression in breast cancer cell lines, paired patient tissues were determined using immunoblotting
and Real-time PCR. 203 human breast cancer tissue samples were analyzed by immunochemistry (IHC) to investigate
the relationship between AGK expression and the clinicopathological features of breast cancer. Functional assays, such
as colony formation, anchorage-independent growth and BrdU assay, and a xenograft tumor model were used to
determine the oncogenic role of AGK in human breast cancer progression. The effect of AGK on FOXO1 transactivity
was further investigated using the luciferase reporter assays, and by detection of the FOXO1 downstream genes.
Results: Herein, we report that AGK was markedly overexpressed in breast cancer cells and clinical tissues.
Immunohistochemical analysis showed that the expression of AGK significantly correlated with patients’
clinicopathologic characteristics, including clinical stage and tumor-nodule-metastasis (TNM) classification. Breast cancer
patients with higher levels of AGK expression had shorter overall survival compared to patients with lower AGK levels.
We gained valuable insights into the mechanism of AGK expression in breast cancer cells by demonstrating that
overexpressing AGK significantly enhanced, whereas silencing endogenous AGK inhibited, the proliferation and
tumorigenicity of breast cancer cells both in vitro and in vivo. Furthermore, overexpression of AGK enhanced G1-S
phase transition in breast cancer cells, which was associated with activation of AKT, suppression of FOXO1 transactivity,
downregulation of cyclin-dependent kinase inhibitors p21Cip1 and p27Kip1 and upregulation of the cell cycle regulator
cyclin D1.
Conclusions: Taken together, these findings provide new evidence that AGK plays an important role in promoting
proliferation and tumorigenesis in human breast cancer and may serve as a novel prognostic biomarker and
therapeutic target in this disease.
Keywords: AGK, Breast cancer, Tumorigenicity, FOXO1Background
Breast cancer is the most common malignancy and leading
cause of cancer-related deaths in females worldwide [1].
Several lines of evidence showed that multiple proteins are
dysregulated in primary tumors and are associated with
the development and progression of breast cancers [2-4].* Correspondence: lb.song1@gmail.com
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unless otherwise stated.Therefore, understanding the roles and molecular mecha-
nisms of these proteins may provide new insights into the
physiology and pathology of cancer and enable the devel-
opment of novel and effective anticancer therapeutics.
FOXO1 is a member of the forkhead box-containing
O subfamily (FOXO) family of transcription factors,
which play vital roles in a variety of biological processes,
including cell cycle arrest, cell death, apoptosis, stress
response, cellular differentiation and metabolism [5,6].
For instance, ectopically expressing FOXO1 transcription-
ally upregulates cell-cycle inhibitors, such as p21Cip1 andtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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cyclin D1 and cyclin D2, which result in G1/S arrest of
cells [7-9]. Activation of FOXO1 could induce apoptosis
through inducing expression of pro-apoptotic proteins,
such as Puma, Bim, TRAIL and Fas ligand (FasL) [10-13].
FOXO1 has also been implicated in DNA repair mecha-
nisms through upregulation of GADD45a by directly bind-
ing to the GADD45 promoter [14]. Conversely, FOXO1
expression is found to be downregulated in multiple
human cancers, including prostate cancer, endometrial
carcinoma, glioblastoma and breast cancer [15-18].
Therefore, FOXO1 is considered to be as a putative tumor
suppressor, and better understanding of the mechanisms
that regulate FOXO1 activity may provide clues of novel
targets for therapeutic intervention.
Acylglycerol kinase (AGK) is found to be abundantly
expressed in the heart, muscle, kidney and brain [19]. By
acting as a lipid kinase, it catalyzes the phosphorylation
of acylglycerols to generate lysophosphatidic acid (LPA)
[19-22], which is a potent lipid mediator that regulates a
number of biological processes [23-25]. Recently, AGK
is reported to be overexpressed in prostate cancer and
esophageal squamous cell carcinoma (ESCC) [19,26,27].
Bektas et al. reported that AGK was upregulated in pros-
tate, uterine, cervical and stomach cancers, and induced
proliferation and migration in prostate cancer cells [19].
Chen et al. showed that overexpression of AGK pro-
moted stem cell-like phenotypes in human ESCC both
in vivo and in vitro and was correlated with progression
and poor prognosis in ESCC [26]. In addition, Nouh
et al. found that AGK expression was significantly corre-
lated with primary Gleason grade of prostate cancer foci
and prostate capsular invasion [27]. These findings have
provided substantial evidence to show that AGK might
contribute to the progression and development of cancer.
However, the clinical significance and biological role of
AGK in human breast cancer remain unclearly.
In this study, we found that AGK was markedly overex-
pressed in breast cancer cells and clinical tissue samples.
Overexpressing AGK dramatically promoted the prolifera-
tion and tumorigenicity of breast cancer cell both in vitro
and in vivo, whereas silencing AGK had the converse ef-
fect. Taken together, our findings suggest that AGK func-
tions as an oncoprotein during breast cancer progression.
Results
AGK overexpression correlates with progression and poor
prognosis in breast cancer
Western blotting and real-time PCR analyses were perfor-
med and showed that AGK mRNA and protein expression
were markedly upregulated in all tested breast cancer cell
lines compared to primary normal breast epithelial cells
(NBECs) (Figure 1A and Additional file 1: Figure S1A).
Consistently, we found that AGK expression was higher ineight human breast cancer tissues than the paired adja-
cent non-tumor tissues (Figure 1B and Additional file 1:
Figure S1B). These results indicate that AGK expression
is upregulated in breast cancer.
To investigate the relationship between AGK expression
and the clinicopathological features of breast cancer, 203
human breast cancer tissue samples were analyzed by IHC.
Consistently, IHC analysis indicated that AGK was mark-
edly upregulated in breast cancer samples (Figure 1C).
Furthermore, statistical analysis of the results revealed that
AGK expression was strongly associated with the clinical
stage (P < 0.001), T classification (P < 0.001), N classifica-
tion (P < 0.001) and M classification (P = 0.003) (Additional
file 2: Table S2). Kaplan-Meier survival curves and log-
rank test showed that AGK expression was significantly
correlated with overall survival (OS) in breast cancer
(P < 0.001; Figure 1D). Similar results were obtained
between patients in clinical stage I–II and III–IV sub-
groups (Additional file 3: Figure S2A-B). Furthermore,
univariate and multivariate analyses indicated that clinical
TNM classification and AGK expression were independ-
ent prognostic factors in breast cancer (Additional file 2:
Table S3), suggesting that AGK might serve as a prognos-
tic indicator of survival in patients with breast cancer.
AGK promotes the proliferation of breast cancer cells
Since AGK expression was correlated with clinical stage
in breast cancer (P < 0.001; Additional file 2: Tables S2
and S3), we then examined the relationship between
AGK and Ki-67 expression. As shown in Figure 2A and
Additional file 2: Tables S2, the tumor areas with the
high levels of AGK staining also showed strong Ki-67
expression, whereas areas with low AGK staining inten-
sities exhibited weak Ki-67 signals (P < 0.001), suggest-
ing that AGK might promote proliferation of breast
cancer cells.
To further investigate the effect of AGK on the prolif-
eration of breast cancer cells by examining gain and loss
of function models (Figure 2B). MTT and colony for-
mation assays showed that the proliferation rate of
AGK-overexpressing cells was significantly higher than
the corresponding vector-control cells, whereas silencing
AGK drastically reduced cell proliferation (Figure 2B-F).
These results provide strong evidence that AGK plays a
critical role in the proliferation of breast cancer cells.
AGK promotes the tumorigenicity of breast cancer cells
both in vitro and in vivo
Next, we investigated the effect of AGK on the tumori-
genicity of breast cancer cells. As shown in Figure 3A,
upregulation of AGK significantly increased, whereas
downregulation of AGK decreased, the anchorage-inde-
pendent growth ability of MCF-7 and SKBR3 cells in soft
agar. Similarly, we observed that MCF-7/AGK tumors
Figure 1 AGK is upregulated in breast cancer. (A and B) Western blotting analysis of AGK expression in normal breast epithelial cells (NBECs)
and 12 breast cancer cell lines (A) and in eight matched primary breast cancer tissues (T) and adjacent noncancerous tissues (N) (B). GAPDH was
used as a loading control. (C) Immunohistochemical analysis of AGK protein expression in normal breast and primary tumor tissues. (D) Kaplan-Meier
overall survival curves and univariate analyses (log-rank) comparing breast cancer patients with low (n = 103) and high (n = 100) AGK-expressing
tumors (P < 0.001).
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whereas the tumors formed by MCF-7/AGK-RNAi cells
grew at a much slower rate than control MCF-7/Scram-
bled-vector tumors (Figure 3B-D). Collectively, these
results indicate that AGK plays a significant role in
the tumorigenicity of breast cancer cells both in vitro
and in vivo.
AGK regulates the G1-S phase transition in breast cancer
cells
To further explore the mechanism by which AGK
promotes proliferation of breast cancer cells, BrdUrd
incorporation and flow-cytometry assays were performed.
As shown in Figure 4A-D, overexpressing AGK signifi-
cantly increased, but silencing AGK reduced, the percent-
age of S phase cells. Further analyses by real-time RT-PCR
and Western blotting showed that the expression of cyclin
dependent kinases (CDK) inhibitors p21Cip1 and p27Kip1,
at both mRNA and protein levels, were drastically reduced
in AGK-overexpressing cells compared to control cells.This was accompanied by a concurrent increase in
the levels of cell cycle regulators cyclin D1 and p-Rb
(Figure 5A,C). Conversely, the expression of p21Cip1
and p27Kip1 significantly increased, whereas expression
of cyclin D1 and p-Rb decreased, in AGK-silenced
cells (Figure 5B-C). Collectively, our results suggest
that AGK promotes cell cycle G1/S transition in breast
cancer cells.
AGK downregulates FOXO1 transactivity and activates AKT
signaling pathway
Previous reports have demonstrated that FOXO1 tran-
scriptionally regulates p21Cip1, p27Kip1 and cyclin D1
[7,8], which prompted us to investigate whether AGK
targeted these genes by modulating the transactivity of
FOXO1. As shown in Figure 6A-B, the transactivity and
expression level of FOXO1 significantly decreased in
AGK-overexpressing cells and increased in AGK-silenced
cells. We also found that AGK expression inversely corre-
lated with FOXO1 in the ten freshly collected clinical
Figure 2 AGK plays a key role in breast cancer cell proliferation and tumorigenicity. (A) AGK expression levels significantly correlated with
Ki-67 expression in human breast cancer tissues (n = 203; P < 0.001). Two representative cases are shown (left) and percentage of specimens with
low or high AGK expression, relative to the levels of Ki-67 staining (right). (B) Western blotting analysis of AGK expression in AGK-infected MCF-7
and SKBR3 cells (upper panel) and AGK-silenced MCF-7 and SKBR3 cells (lower panel). GAPDH was used as a loading control. (C-F) MTT assay
(C, E) and colony formation assay (D, F) indicated that the growth rate increased in AGK-overexpressing cells and decreased in AGK-silenced cells.
The absorbance at day 1–5 was normalized to the absorbance at day 0 used as control (100%). The number of colonies was quantified in the
colony formation assay. Each bar represents the mean ± SD of three independent experiments. *P < 0.05.
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AKT kinase is known to play a key role in phosphorylating
and repressing FOXO transcriptional activity [8]. As
predicted, overexpressing AGK drastically increased, but
silencing AGK decreased, the level of p-AKT and p-GSK-
3β (Figure 6B), suggesting that AGK contributes to modu-
lation of AKT/FOXO1 and AKT/GSK-3β signalings.We further examined the role of FOXO1 in AGK-
mediated cell proliferation. As shown in Additional file 4:
Figure S3A, the luciferase activity of the FOXO1 reporter
was significantly decreased in AGK-silenced cells after
FOXO1 siRNA(s) transfection. Additional knockdown of
FOXO1 in AGK-silenced cells decreased p27 Kip1 and
p21Cip1 expression but increased cyclin D1 expression
Figure 3 AGK promotes the tumorigenicity of breast cancer cells in vitro and in vivo. (A) Anchorage-independent growth assays of
AGK-overexpressing cells and AGK-silenced cells. The number of colonies with a diameter larger than 0.1 mm was quantified after 10 days of
culture. (B-D) Xenograft model in nude mice. MCF-7-AGK, MCF-7-AGK-RNAi and the respective control cells were inoculated into the fat-pad of
nude mice (n = 5/group). (B): Representative images of tumor-bearing mice (left panel) and images of the tumors from all mice in each group
(right panel). (C) Tumor volumes were measured on the indicated days. (D) Mean tumor weights. Each bar represents the mean ± SD of three
independent experiments. *P < 0.05.
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more, MTT and colony formation assays showed that si-
lencing FOXO1 restored the growth rate of AGK-silenced
cells (Figure 6E-F and Additional file 4: Figure S3C).
Taken together, our results suggest that FOXO1 plays a
critical role in the pro-proliferative effect of AGK on
breast cancer cells.
Discussion
The key findings presented in this study suggest that
AGK is markedly upregulated in breast cancer cells andits ectopic expression promotes the proliferation and
tumorigenicity of breast cancer cells both in vitro and
in vivo. The mechanistic basis for the pro-proliferative
effect of AGK might be linked to activation of the AKT
signaling pathway and subsequent inhibition of FOXO1
transcriptional activity, which would lead to altered ex-
pression of cell-cycle related genes, including the down-
regulation of CDK inhibitors, p21Cip1 p27Kip1 and
upregulation of cyclin D1. Our results have provided new
insights into the role of AGK in the progression of human
breast cancer, indicating that targeting AGK may offer a
Figure 4 AGK regulates the G1-S phase cell cycle transition in breast cancer cells. (A) Representative micrographs (left) and quantification
(right) of BrdU incorporation by the indicated cells. (B) Flow cytometric analysis of vector control and AGK-overexpressing cells. (C) Representative
micrographs (left) and quantification (right) of BrdU incorporation by vector and AGK shRNA-infected cells. (D) Flow cytometric analysis of vector
and AGK shRNA-infected cells. Each bar represents the mean ± SD of three independent experiments. *P < 0.05.
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Figure 5 AGK alters expression in G1-S phase cell-cycle regulators. (A and B) Real-time PCR analysis of p21Cip1, p27Kip1 and cyclin D1 mRNA
expression in AGK-infected cells (A) or AGK-shRNA infected cells (B). Gene expression levels were normalized to GAPDH. (C) Western blotting
analysis of p21Cip1, p27Kip1, cyclin D1, p-Rb and total Rb protein expression in AGK-infected cells and AGK-shRNA infected cells; GAPDH was used
as a loading control. Each bar represents the mean ± SD of three independent experiments. *P < 0.05.
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with breast cancer.
Although AGK has been shown to be overexpressed in
several types of cancer and has been associated with
cancer progression and development [19,26,27], its clinical
significance and biological role in human breast cancer
remains unclear. In this study, we found that AGK expres-
sion was upregulated in a large cohort of human breast
cancer tissues, and was significantly correlated with theclinicopathologic characteristics of breast cancer, includ-
ing clinical stage and TNM classification. Furthermore,
survival analyses showed that patients with higher levels
of AGK expression had shorter overall survival time com-
pared to those with lower AGK expression, suggesting
that AGK may represent a novel predictor for prognosis
and survival in breast cancer. Several reports have also
provided evidence that AGK is involved in the survival
and motility of malignant phenotypes of cancer cells and
Figure 6 AGK downregulates FOXO1 transaactivity and activates the AKT pathway. (A) Relative FOXO1 reporter activity in AGK-infected
cells, AGK-shRNA infected cells and control cells. (B) Western blotting analysis of phosphorylated-Akt (p-Akt), total Akt, phosphorylated-GSK-3β
(p-GSK-3β), total GSK-3β, phosphorylated-FOXO1 (Ser256) and total FOXO1 proteins in MGF-7 and SKBR3 breast cancer cells. GAPDH was used as
a loading control. (C) Expression (upper panel) and correlation analysis (lower panel) of AGK and FOXO1 expression in 10 freshly isolated human
breast cancer samples. (D) Western blotting analysis of p21Cip1, p27Kip1, cyclin D1 and FOXO1 proteins in the indicated breast cancer cell lines.
GAPDH was used as a loading control. (E, F) The MTT assay shows that silencing FOXO1 increased the proliferation of AGK-silenced cells as
determined by an MTT assay. Error bars represent SD from three independent experiments. *P < 0.05.
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ment with these reports, we found that AGK was strongly
expressed in highly proliferative lesions of human breast
cancer, as indicated by a significant correlation between
AGK and Ki-67 expression (P < 0.001). Combined with
our observation that upregulation of AGK was implicated
in the proliferation and tumorigenicity of breast cancer
cells both in vivo and in vitro. Therefore, our results sup-
port the proposal that AGK is a proliferation-promoting
and oncogenic protein in breast cancer cells.
It has been established that FOXO1 functions as a
tumor suppressor. Consistently, FOXO1 expression is
reported to be downregulated in multiple cancer types,
such as breast cancer, prostate cancer, glioblastoma and
endometrial carcinoma [15-18]. FOXO1 has been dem-
onstrated to be involved in multiple biological processes
through transcriptional regulation of their downstream
efforts, such as CDK inhibitors p21Cip1, p27Kip1and
p57kip2, cell-cycle related genes cyclin D1/D2, and pro-
apoptotic proteins, such as Puma, Bim, TRAIL and FasL
[7-13,28,29]. We showed that depletion of FOXO1 re-
stored the growth rate of AGK-silenced breast cancer cells,
indicating that FOXO1 plays a critical role in the pro-
proliferative effect of AGK on breast cancer cells.
By showing that AGK overexpression decreased the
transactivation of FOXO1 and its downstream targets,
we hypothesized that FOXO1 was involved in AGK-
mediated proliferative mechanisms. It has been reported
that phosphorylation of FOXO1 (Ser256) by AKT results
in downregulation of FOXO1 transactivity via ubiquitin-
proteasome-mediated degradation [30-32]. We observed
similar effects, in that the levels of phospho-AKT and
phospho-FOXO1 were increased in AGK-overexpressing
cells and decreased in AGK-silenced cells. This sug-
gested that the mechanism underlying AGK-mediated
FOXO1 downregulation might be through activation of
AKT. AKT is a major downstream effector of epidermal
growth factor receptor EGFR and the non-receptor tyro-
sine kinase JAK2 [33,34]. Interestingly, it has been repor-
ted that AGK overexpression promotes aggressiveness in
prostate cancer cells through activation of EGFR, and that
upregulation of AGK promotes the stem cell-like pheno-
type in ESCC by sustaining JAK2 activity [15,22]. Mean-
while, we also observed that the phosphorylation level of
GSK-3β, a downstream target protein of Akt, increased in
the AGK-overexpressing cells and decreased in the AGK
silenced cells. It has been reported that inactivation of
GSK3β indicated by increased p-GSK3β was found in
approximately half of the invasive mammary carcinomas,
and significantly correlated with a worse clinical outcome
[35]. Phosphorylation mediated suppression of GSK3β
promotes breast tumor initiation and metastasis, and
reduced phosphorylation of GSK3β efficiently inhibit
cancer stem cell-like phenotypes in breast cancer [36,37].Therefore, the role of AGK-modulation of GSK-3β activity
in breast cancer cells is currently under investigation by
our group.
Conclusions
In summary, our results have demonstrated that AGK
plays an important role in human breast cancer pro-
gression and have provided insights into the underlying
mechanisms. Establishing the precise role played by AGK
in breast cancer progression will not only advance our
understanding of the biology of breast cancer but may
offer a mechanism for a novel therapeutic strategy via
suppression of AGK expression in breast cancer cells.
Furthermore, our results suggest a potential role for AGK
as a clinical predictor of disease progression, prognosis
and survival in patients with breast cancer. Evaluating the




Primary normal breast epithelial cells (NBECs) were
established as previously described [38]. Breast cancer
cell lines, including MCF-7, BT-549, ZR-75-1, SKBR3,
MDA-MB-468, MDA-MB-435, Bcap37, MDA-MB-415,
MDA-MB-361, T47D, MDA-MB-231 and ZR-75-30 were
cultured in DMEM medium (Gibco, Grand Island, NY)
supplemented with 10% FBS (HyClone, Logan, UT).
Patient information and tissue specimens
This study was conducted on a total of 203 paraffin-
embedded, archived breast cancer samples, which had
been histopathologically and clinically diagnosed at the
Sun Yat-sen University Cancer Center from 1998 to
2006. Clinical and clinicopathological classification and
stage were determined according to American Joint Com-
mittee on Cancer (AJCC) criteria [39] and summarized in
Additional file 2: Table S1. Ethics approval and prior
patient consent had been obtained from the Institutional
Research Ethics Committee for the use of the clinical
specimens for research purposes.
Vectors and retroviral infection
The human AGK gene was PCR-amplified from cDNA
and cloned into the pSin-EF2 lentiviral vector, and
shRNAs targeting AGK were cloned into the pSuper-
retro viral vector, as previously described [26]. Retroviral
production and infection were performed as previously
described [40]. Stable cell lines expressing AGK or AGK
shRNAs were selected for 10 days with 0.5 μg/ml puro-
mycin. The reporter plasmid for detecting the transcrip-
tional activity of FOXO1 was generated as described
previously [41].
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Immunohistochemistry (IHC) and quantification of
AGK expression were performed by two independent
pathologists, as previously described [26]. Both sets of
results were combined to give a mean score for further
comparative evaluations. Briefly, the IHC score, or stain-
ing index (SI), was determined by combining the score
for the percentage of positively-stained tumor cells with
the grade of the staining intensity. The percentages of
positively-stained tumor cells were scored as follows: 0,
no positive tumor cells; 1, <10%; 2, 10%–35%; 3, 35%–
75%; 4, >75%. The staining intensities were graded as
follows: 1, no staining; 2, weak staining (light yellow); 3,
moderate staining (yellow–brown); 4, strong staining
(brown). We used this method to evaluate AGK expres-
sion in benign breast epithelia and malignant lesions.
The possible scores were 0, 2, 3, 4, 6, 8, 9, 12 and
16; SI ≥8 was defined as high expression and SI <8 was
defined as low expression.
Western blotting
Western blotting was carried out according to standard
methods as described previously [38], by using anti-AGK
antibody (Epitomics, Burlingame, CA), anti-p21Cip1, anti-
p27Kip1, anti-cyclin D1, anti-Rb, anti-phosphorylated-Rb,
anti-AKT, anti-phosphorylated-AKT, anti-FOXO1, anti-
phosphorylated-FOXO1 (Ser256) (Cell Signaling, Danvers,
MA). The membranes were stripped and re-probed with
an anti-GAPDH antibody (Sigma, Saint Louis, MI) as a
loading control.
MTT cell viability assay
Cells were seeded in 96-well plates at a density of 2 × 103
cells/well. At each time point, cells were stained with
100 μl sterile MTT dye (0.5 mg/ml, Sigma) for 4 hours at
37°C, followed by removal of the culture medium and
addition of 100 μl of dimethyl sulphoxide (Sigma). The
absorbance was measured at 570 nm, with 655 nm as the
reference wavelength. The absorbance at day 1–5 was nor-
malized to the absorbance at day 0 used as control (100%).
Each experiment was performed in triplicates.
Colony formation assay
Cells were plated in 6-well plated (5 × 102 cells) and
cultured for 10 days. The colonies were stained with 1%
crystal violet for 30 seconds after fixation with 4% for-
maldehyde for 5 minutes. Colonies were counted and the
resultes were shown as the fold change compared to vec-
tor control cells.
Anchorage-independent growth ability assay
Five hundred cells were trypsinized and suspended in
2 ml complete medium plus 0.3% agar (Sigma, Saint
Louis, MI). The agar-cell mixture was plated on top of abottom layer with 1% agar completed medium mixture.
About 10 days, viable colonies that were larger than
0.1 mm were counted. The experiment was carried out
for each cell line in triplicates.
Bromodeoxyuridine (BrdU) labeling and
immunofluorescence
Cells (5 × 104) were plated on coverslips. After 24 hours,
cells were incubated with BrdU for 1 h and stained with
anti-BrdU antibody (Upstate, Billerica, MA) according to
the manufacturer’s instruction. After washing three
times with PBS containing 1% Triton X-100, the cells
were treated with anti-mouse TRITC fluorescent conju-
gated secondary antibodies to visualize anti-BrdU labeled
cells. BrdU positive cells were counted under a laser scan-
ning microscope (Axioskop 2 plus; Carl Zeiss Co. Ltd.) in
ten random chosen fields from three independent sam-
ples. Percentage of BrdU positive cells was then calculated,
and the results are presented as the mean ± SD.
Flow cytometry
Cells were harvested, washed with cold PBS, and proc-
essed for cell cycle analysis by using flow cytometry.
Briefly, the cells were fixed in 75% ethanol and stored
at −20°C overnight for later analysis. The fixed cells
were centrifuged at 1,000 rpm for 5 min and washed
with cold PBS twice. RNase A (20 μg/ml final concentra-
tion) and propidium iodide staining solution (50 μg/ml
final concentration) were added to the cells and incubated
for 30 minutes at 37°C in the dark. Twenty thousand cells
were analyzed by using a CytomicsTM FC 500 instrument
(Beckman Coulter, USA) equipped with CXP software.
Modfit LT 3.1 trial cell cycle analysis software was used to
determine the percentage of cells in the different phases of
the cell cycle.
Xenografted tumor model
Female BALB/c nude mice (5 ~ 6 weeks of age, 18 ~ 20 g)
were purchased from the Slac-Jingda Laboratory Animal
(Hunan, China), and were housed in barrier facilities on a
12-hour light/dark cycle. All experimental procedures
were approved by the Institutional Animal Care and Use
Committee of Sun Yat-sen University. The BALB/c nude
mice were randomly divided into 4 groups (n = 5/group).
A 0.72 mg E2 60-day release pellet (Innovative Research
of America) was implanted subcutaneously on the dorsal
side of each mouse 1 day before tumor cell implantation
to support the growth of the estrogen-dependent MCF-7
cell derived tumors. For tumor cell implantation, MCF-7-
AGK or MCF-7-AGK-RNAi or their respective control
cells (2 × 106) in 200 μl of the mixture were injected into
the mammary fat pads of mice. Tumors were examined
twice weekly; length, width, and thickness measurements
were obtained with calipers and tumor volumes were
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mors were excised and weighed.Statistical analysis
Statistical analyses were performed using the SPSS version
13.0 statistical software package. Statistical tests for data
analysis included log rank test, χ2 test, spearman-rank
correlation test and Student’s 2-tailed t test. Multivariate
statistical analysis was performed using a Cox regression
model. Data represent mean ± SD. A P-value < 0.05 was
considered statistically significant.Additional files
Additional file 1: Figure S1. AGK is upregulated in breast cancer. (A-B)
Real-time PCR analysis of AGK mRNA expression in NBECs and twelve
breast cancer cell lines (A), and in matched primary breast cancer tissues
(T) and the adjacent noncancerous tissues (N) (B). Expression levels were
normalized to GAPDH. Error bars represent SD from three independent
experiments. *P < 0.05.
Additional file 2: Table S1. Clinicopathological characteristics of
patient samples and expression of AGK in Breast Cancer. Table S2.
Correlation between AGK expression and clinicopathologic characteristics
of Breast Cancer. Table S3. Univariate and multivariate analyses of
various prognostic parameters in patients with Breast cancer
Cox-regression analysis.
Additional file 3: Figure S2. (A-B) Kaplan-Meier overall survival curves
and log-rank test in breast cancer patients stratified by clinical stage I-II
(n = 131) (A) and clinical stage III-IV (n = 72) (B). The curves compare
patients with high and low expression levels of AGK.
Additional file 4: Figure S3. FOXO1 plays an important role in
AGK-mediated proliferation. (A) Relative FOXO1 reporter activity in
AGK-silenced MCF-7 and MDA-MB-231 cells after transfection with FOXO1
siRNA(s). (B) Real-time PCR analysis of p21Cip1, p27Kip1 and cyclin D1
mRNA expression in AGK-silenced MCF-7 and MDA-MB-231 cells after
transfection with FOXO1 siRNA(s). Expression levels were normalized to
GAPDH. (C) Quantification of colony formation assays in indicated cells.
Error bars represent SD from three independent experiments. *P < 0.05.Abbreviations
AGK: Acylglycerol kinase; IHC: Immunochemistry; TNM: Tumor-nodule-
metastasis; FOXO: Forkhead box-containing O subfamily; FASL: Fas ligand;
LPA: Lysophosphatidic acid; OS: Overall survival; CDK: Cyclin dependent
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